SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
or Other Jurisdiction
|(Commission File Number)||(IRS
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code
Name, or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Exchange Act:
(Title of each class)
(Name of exchange on which registered)
|The Stock Market LLC|
|TheStock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 23, 2022, Jasper Therapeutics, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Meeting”). At the Meeting, a total of 19,415,543 shares of the Company’s voting common stock, or approximately 53% of the 36,579,906 shares of the Company’s voting common stock issued and outstanding as of April 26, 2022, the record date for the Meeting, were represented in person or by proxy.
At the Meeting, the Company’s stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022.
Set forth below is a brief description of each matter voted upon at the Meeting and the voting results with respect to each matter.
Proposal No. 1: To elect two Class I directors to serve until the 2025 annual meeting of stockholders and until their successors are duly elected and qualified.
|Director Nominee||Votes For||Votes Withheld||Broker Non-Votes|
|Kurt von Emster||17,769,058||324,016||1,322,469|
|Lawrence Klein, Ph.D.||17,890,093||202,981||1,322,469|
Proposal No. 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2022.
|Votes For||Votes Against||Abstentions|
Item 9.01. Financial Statements and Exhibits.
|104||Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
JASPER THERAPEUTICS, INC.
|Date: June 27, 2022||By:||/s/ Jeet Mahal|
|Name: Jeet Mahal|
Chief Operating Officer and |
Chief Financial Officer